Michelle Lally

Michelle Lally

Auto-generated profile, based on publicly available information

Michelle Lally

Department of Medicine, Alpert Medical School of Brown University, Providence, Rhode Island, USA

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2015 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
ELEric Londin
Eric Londin
PLPhillipe Loher
Phillipe Loher
ATAristeidis G Telonis
Aristeidis G Telonis
KQKevin Quann
Kevin Quann
PCPeter Clark
Peter Clark
Isidore RigoutsosIsidore Rigoutsos
Isidore Rigoutsos
Significance: MicroRNAs (miRNAs) are small ∼22-nt RNAs that are important regulators of posttranscriptional gene expression. Since their initial discovery, they have been shown to be involved in many cellular processes, and their misexpression is associated with disease etiology. Currently, nearly 2,800 human miRNAs are annotated in public repositories. A key question in miRNA research is how many miRNAs are harbored by the human genome. To answer this question, we examined 1,323 short RNA sequence samples and identified 3,707 novel miRNAs, many of which are human-specific and tissue-specific. Our findings suggest that the human genome expresses a greater number of miRNAs than has previously been appreciated and that many more miRNA molecules may play key roles in disease etiology.

1 June 2008 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
FPFrances H. Priddy
Frances H. Priddy
DBDeborah Brown
Deborah Brown
JKJames Kublin
James Kublin
KMKathleen Monahan
Kathleen Monahan
DWDavid P. Wright
David P. Wright
EQErin Quirk
Erin Quirk
Background. The safety and immunogenicity of the MRK adenovirus type 5 human immunodeficiency virus type 1 clade B gag/pol/nef vaccine, a replication

1 April 2013 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
SHSybil G. Hosek
Sybil G. Hosek
GSGeorge Siberry
George Siberry
MBMargo Bell
Margo Bell
MLMichelle Lally
Michelle Lally
BKBill Kapogiannis
Bill Kapogiannis
CWCraig M. Wilson
Craig M. Wilson
Background: This study examined the feasibility of a combination prevention intervention for young men who have sex with men (YMSM), an anticipated target population for HIV preexposure prophylaxis (PrEP). Methods: Project PrEPare, a pilot study using a randomized 3-arm design, compared an efficacious behavioral HIV prevention intervention (Many Men, Many Voices—3 MV) alone, 3 MV combined with PrEP (tenofovir/emtricitabine), and 3 MV combined with placebo. Eligible participants were 18- to 22-year-old HIV-uninfected men who reported unprotected anal intercourse in the past year. Participants were screened for preliminary eligibility at youth venues and community organizations and were also referred through social networks. Laboratory screening determined final eligibility. Behavioral and biomedical data were collected at baseline and every 4 weeks thereafter for 24 weeks. Results: Sixty-eight youth (mean age = 19.97 years; 53% African American, 40% Latino) were enrolled; 58 were randomized. Self-reported medication adherence averaged 62% (range, 43%–83%), whereas rates of detectable tenofovir in plasma of participants in the emtricitabine/tenofovir disoproxil fumarate arm ranged from 63.2% (week 4) to 20% (week 24). There were 5 ≥ grade 2 adverse events possibly/probably related to the study medication. Sexual risk behavior declined from baseline to week 24 in all study arms. Conclusions: The feasibility of enrolling at-risk youth, particularly young men who have sex with men of color, into Project PrEPare has been demonstrated. The acceptability of the group intervention along with counseling and testing was high. Self-reported medication adherence and corresponding plasma drug concentrations were low indicating the need for enhanced adherence counseling. Exploration of PrEP use among youth in nonrandomized open label trials is warranted.

3 August 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
GCGavin J. Churchyard
Gavin J. Churchyard
CMCecilia Morgan
Cecilia Morgan
EAElizabeth Adams
Elizabeth Adams
JHJohn Hural
John Hural
BGBarney S. Graham
Barney S. Graham
TNThe Niaid Hiv Vaccine Trials Network
The Niaid Hiv Vaccine Trials Network
The safety and immunogenicity of a vaccine regimen consisting of a 6-plasmid HIV-1 DNA prime (envA, envB, envC, gagB, polB, nefB) boosted by a recombinant adenovirus serotype-5 (rAd5) HIV-1 with matching inserts was evaluated in HIV-seronegative participants from South Africa, United States, Latin America and the Caribbean. 480 participants were evenly randomized to receive either: DNA (4 mg IM by Biojector) at 0, 1 and 2 months, followed by rAd5 (1010 PU IM by needle/syringe) at 6 months; or placebo. Participants were monitored for reactogenicity and adverse events throughout the 12-month study. Peak and duration of HIV-specific humoral and cellular immune responses were evaluated after the prime and boost. The vaccine was well tolerated and safe. T-cell responses, detected by interferon-γ (IFN-γ) ELISpot to global potential T-cell epitopes (PTEs) were observed in 70.8% (136/192) of vaccine recipients overall, most frequently to Gag (54.7%) and to Env (54.2%). In U.S. vaccine recipients T-cell responses were less frequent in Ad5 sero-positive versus sero-negative vaccine recipients (62.5% versus 85.7% respectively, p = 0.035). The frequency of HIV-specific CD4+ and CD8+ T-cell responses detected by intracellular cytokine staining were similar (41.8% and 47.2% respectively) and most secreted ≥2 cytokines. The vaccine induced a high frequency (83.7%–94.6%) of binding antibody responses to consensus Group M, and Clades A, B and C gp140 Env oligomers. Antibody responses to Gag were elicited in 46% of vaccine recipients. The vaccine regimen was well-tolerated and induced polyfunctional CD4+ and CD8+ T-cells and multi-clade anti-Env binding antibodies. ClinicalTrials.gov NCT00125970

26 February 2015 in Journal of the International AIDS Society
Verified
Journal Article
Open access
AKAnn E Kurth
Ann E Kurth
MLMichelle A Lally
Michelle A Lally
ACAugustine T Choko
Augustine T Choko
IIIrene W Inwani
Irene W Inwani
JFJ Dennis Fortenberry
J Dennis Fortenberry
Introduction: HIV testing is the portal to serostatus knowledge that can empower linkage to care for HIV treatment and HIV prevention. However, young people's access to HIV testing is uneven worldwide. The objective of this paper is to review the context and concerns faced by youth around HIV testing in low‐ as well as high‐income country settings.Discussion: HIV testing is a critical entry point for primary and secondary prevention as well as care and treatment for young people including key populations of vulnerable youth. We provide a framework for thinking about the role of testing in the continuum of prevention and care for young people. Brief case study examples from Kenya and the US illustrate some of the common barriers and issues involved for young people.Conclusions: Young people worldwide need more routine access to HIV testing services that effectively address the developmental, socio‐political and other issues faced by young women and men.

1 November 2000 in The American Journal of Medicine
Verified
Journal Article
Closed access
EMEleftherios Mylonakis
Eleftherios Mylonakis
MPMaria Paliou
Maria Paliou
MLMichelle Lally
Michelle Lally
TFTimothy P Flanigan
Timothy P Flanigan
JRJosiah D Rich
Josiah D Rich